Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

Oruka Therapeutics (ORKA) will attend the 2026 Morgan Stanley Global Healthcare Conference in New York, NY, taking place from September 14-16, 2026.

Rhea-AI Summary

Oruka Therapeutics (ORKA) will attend the 2026 Morgan Stanley Global Healthcare Conference in New York, NY, taking place from September 14-16, 2026.

Oruka is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, including plaque psoriasis and hidradenitis suppurativa.

Argus Sep 10 session

+0.16% close to close Open Argus

Details

News Market Reaction – ORKA

On Sep 10, the first trading day after this news, ORKA closed 0.16% above the previous close.

Data tracked by StockTitan Argus for the Sep 10 session.

Key Figures

Conference dates: September 14-16, 2026

Conference dates

September 14-16, 2026

2026 Morgan Stanley Global Healthcare Conference

Key Terms

plaque psoriasis, hidradenitis suppurativa, biologics

3 terms

plaque psoriasis medical

"treatment of chronic skin diseases including plaque psoriasis"

A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.

hidradenitis suppurativa medical

"including plaque psoriasis and hidradenitis suppurativa"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

biologics medical

"developing novel biologics designed to set a new standard"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.

About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com